Universal Health Services, Inc.

The proposed 2.4% CMS payment rate increase for hospitals has buoyed investor sentiment, and UHS demonstrated resilient Q1 2026 revenue growth of 9.6% YOY. Full-year 2026 guidance for both revenue and EPS came in ahead of Wall Street projections, suggesting the company can navigate reimbursement headwinds.

Ongoing adjustments to Medicaid and other public reimbursement programs have increased uncertainty about the future revenue mix, contributing to a 27.4% YTD stock decline. Policy instability poses a sustained risk to revenue quality, and UHS's earnings are forecast to decline at 0.3% per annum despite top-line growth.

The consensus price target of $210–$214 implies roughly 32–42% upside from current levels, with 7 'Strong Buy' ratings among 20 covering analysts. The stock is trading near 52-week lows, attracting investors on valuation grounds, and Wall Street's overall consensus rating remains 'Moderate Buy.'

Technical indicators paint a starkly different picture: UHS holds sell signals from both short- and long-term moving averages, an RSI14 of 16 indicating oversold conditions, and a negative MACD signal. The stock is down 28% year-to-date and is forecast to fall an additional 8.30% over the next three months.

Wall Street analysts project UHS diluted EPS to grow 8% annually to $23.47 in FY2026 and a further 8.2% to $25.40 in FY2027. UHS has beaten consensus estimates in three of the past four quarters, and Cantor Fitzgerald noted stable inpatient psychiatric openings and Q2 performance contrasting with weaker rival trends.

Despite healthy top-line revenue growth of 5% per annum, earnings are forecast to decline at 0.3% annually, signaling margin compression. The stock dropped 9.5% intraday after a better-than-expected Q1 report, reflecting deep investor skepticism about whether near-term earnings improvements are durable.